TY - JOUR
T1 - Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702)
T2 - Alliance
AU - Ganti, Apar K.
AU - Fruth, Briant
AU - Rimner, Andreas
AU - Waqar, Saiama
AU - Mix, Michael D.
AU - Petty, W. Jeffrey
AU - Stinchcombe, Thomas E.
AU - Vokes, Everett E.
AU - Bogart, Jeffrey A.
AU - Dueck, Amylou C.
N1 - Publisher Copyright:
© 2024 American Cancer Society.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Background: CALGB 30610 trial demonstrated that once daily thoracic radiotherapy (TRT) was not superior compared to standard twice daily TRT, in patients with limited stage small cell lung cancer. Quality of life outcomes may help oncologists decide the best treatment approach. Methods: A total of 417 patients on CALGB 30610 participated in the quality-of-life substudy (CALGB 70702), which included the FACT Trial Outcome Index-Lung Cancer (FACT-L TOI), FACT-Esophageal Cancer (FACT-E) Eating and Swallowing Indices, ECOG Acute Esophagitis Scale, Hospital Anxiety and Depression Scale (HADS), difficulty swallowing, EQ-5D, and treatment convenience assessment at baseline, 3, 5, 7, 12, 26, and 52 weeks after starting TRT. Primary end points included FACT-L TOI and FACT-E at 12 weeks. Mean changes from baseline were compared between arms using general linear mixed models. Results: FACT-L worsening was more in the twice daily arm at week 3 (–1.0 vs. –7.0). FACT-L TOI worsening was less at week 3 (–2.9 vs. –7.6) and greater at week 12 (–7.6 vs. –2.8) in the once daily arm. The once daily arm had a lower EQ-5D index worsening at 3 weeks (0.01 vs. –0.02). Increase in acute esophagitis score (1.06 vs. 2.89; p <.001) and difficulty swallowing (0.39 vs. 1.14) were greater in the twice daily arm at week 3. A total of 74.5% of patients on the once daily arm felt that treatment was convenient, compared to 67% of patients in the twice daily arm (p =.03). Conclusions: The once daily arm had better quality-of-life scores earlier during treatment and was perceived to be more convenient.
AB - Background: CALGB 30610 trial demonstrated that once daily thoracic radiotherapy (TRT) was not superior compared to standard twice daily TRT, in patients with limited stage small cell lung cancer. Quality of life outcomes may help oncologists decide the best treatment approach. Methods: A total of 417 patients on CALGB 30610 participated in the quality-of-life substudy (CALGB 70702), which included the FACT Trial Outcome Index-Lung Cancer (FACT-L TOI), FACT-Esophageal Cancer (FACT-E) Eating and Swallowing Indices, ECOG Acute Esophagitis Scale, Hospital Anxiety and Depression Scale (HADS), difficulty swallowing, EQ-5D, and treatment convenience assessment at baseline, 3, 5, 7, 12, 26, and 52 weeks after starting TRT. Primary end points included FACT-L TOI and FACT-E at 12 weeks. Mean changes from baseline were compared between arms using general linear mixed models. Results: FACT-L worsening was more in the twice daily arm at week 3 (–1.0 vs. –7.0). FACT-L TOI worsening was less at week 3 (–2.9 vs. –7.6) and greater at week 12 (–7.6 vs. –2.8) in the once daily arm. The once daily arm had a lower EQ-5D index worsening at 3 weeks (0.01 vs. –0.02). Increase in acute esophagitis score (1.06 vs. 2.89; p <.001) and difficulty swallowing (0.39 vs. 1.14) were greater in the twice daily arm at week 3. A total of 74.5% of patients on the once daily arm felt that treatment was convenient, compared to 67% of patients in the twice daily arm (p =.03). Conclusions: The once daily arm had better quality-of-life scores earlier during treatment and was perceived to be more convenient.
KW - concurrent chemotherapy and radiation
KW - limited stage small cell lung cancer
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85213797948&partnerID=8YFLogxK
U2 - 10.1002/cncr.35663
DO - 10.1002/cncr.35663
M3 - Article
C2 - 39580636
AN - SCOPUS:85213797948
SN - 0008-543X
VL - 131
JO - Cancer
JF - Cancer
IS - 1
M1 - e35663
ER -